CN113549671B - Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient - Google Patents

Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient Download PDF

Info

Publication number
CN113549671B
CN113549671B CN202110830622.7A CN202110830622A CN113549671B CN 113549671 B CN113549671 B CN 113549671B CN 202110830622 A CN202110830622 A CN 202110830622A CN 113549671 B CN113549671 B CN 113549671B
Authority
CN
China
Prior art keywords
sarcopenia
mhd
megamonas
intestinal flora
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110830622.7A
Other languages
Chinese (zh)
Other versions
CN113549671A (en
Inventor
周起帆
张海林
尹丽霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Peoples Hospital of Lianyungang
Original Assignee
First Peoples Hospital of Lianyungang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Peoples Hospital of Lianyungang filed Critical First Peoples Hospital of Lianyungang
Priority to CN202110830622.7A priority Critical patent/CN113549671B/en
Publication of CN113549671A publication Critical patent/CN113549671A/en
Application granted granted Critical
Publication of CN113549671B publication Critical patent/CN113549671B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The application discloses an intestinal flora for diagnosing sarcopenia of a patient with maintenance hemodialysis, wherein the intestinal flora at least comprises Megamonas; the relative abundance of Megamonas is significantly reduced (P < 0.001) in patients with MHD sarcopenia. The diagnostic value of Megamonas on MHD sarcopenia is expressed by ROC and AUC, the AUC is 0.787, the sensitivity is 0.867, the specificity is 0.800, and the diagnostic effect of Megamonas on MHD sarcopenia is higher.

Description

Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient
Technical Field
The application belongs to the technical field of biology, and particularly relates to an intestinal flora for diagnosing sarcopenia of a maintenance hemodialysis patient.
Background
Sarcopenia is a group of degenerative syndromes characterized by a decrease in skeletal muscle mass, with a decrease in muscle strength and/or a decrease in body function. Patients with maintenance hemodialysis (maintenance hemodialysis, MHD) have a high risk of developing sarcopenia due to negative protein balance caused by kidney disease, dialysis treatment, and chronic inflammation, coupled with dietary restrictions and reduced physical activity. Sarcopenia not only reduces the somatic function of MHD patients, impairs the ability to live daily life, leads to a reduction in the quality of life of the patients, but also increases hospitalization risks and hospitalization costs, and even is an independent predictor of mortality of MHD patients, bringing a large burden to the home and society.
Intestinal flora is capable of producing a variety of metabolites that affect the health of the human body, which in turn affects the health status of the host. The previous research considers that the intestinal flora influences the muscle quality and the function of a host by directly influencing the inflammation environment, the bioavailability of nutrient substances, lipid metabolism and energy supply of the host, but the human body research is limited mainly based on animal models, and the characteristics of the intestinal flora of the MHD sarcopenia crowd are not directly explored. The characteristics of intestinal flora of patients suffering from MHD sarcopenia are studied, and the marker genus related to sarcopenia is found, so that the method has important significance in revealing pathogenesis of MHD sarcopenia and realizing diagnosis and treatment of sarcopenia.
Disclosure of Invention
The application aims to provide intestinal flora related to the occurrence and development of sarcopenia of a hemodialysis patient, which is used for diagnosing and treating the sarcopenia of the hemodialysis patient.
In order to achieve the above purpose, the technical scheme adopted by the application is as follows:
an intestinal flora for diagnosing sarcopenia in a patient undergoing maintenance hemodialysis, said intestinal flora comprising at least Megamonas.
A method of screening for intestinal flora for sarcopenia in a maintenance hemodialysis patient, the method comprising:
step 1: collecting fresh feces of a patient suffering from hemodialysis sarcopenia and a patient suffering from hemodialysis non-sarcopenia respectively, immediately placing the feces into-80 ℃ for preservation and standby detection after sampling;
step 2:16S rRNA sequencing, extracting genome DNA aiming at sampling, and detecting the quality of the genome DNA by agarose gel electrophoresis;
step 3: PCR amplification of the V3-V4 variable region of bacterial 16S rRNA with primers 338F and 806R; mixing PCR products according to equal proportion, and then purifying by using a DNA purifying column;
step 4: constructing a library of the purified amplified fragments according to standard operation procedures of an IlluminaMiSeq platform; sequencing using the Hiseq2500 platform;
step 5: splicing the original sequencing sequences by using FLASH 1.2.11 software, filtering by using Trimmomatic 0.33 software, and removing the chimera by using UCHIME 8.1 software to obtain high-quality Tags sequences;
step 6: OTU clustering of sequences at a level of 97% similarity using USEARCH 10.0 software, and removal of single sequences and chimeras during clustering; the OTU at 97% level with RDP classifer was used for biometric analysis and the Silva database (SSU 123) was used for comparison;
step 7: the Kruskal-Wallis rank sum test using SPSS 26.0 software analyzes the group-to-group differential flora, namely Megamonas, and the diagnostic value of the differential flora on MHD sarcopenia is evaluated by using ROC curve and area under the curve.
Preferably, the mass of genomic DNA, including the concentration and purity of DNA, is detected by 1.8% agarose gel electrophoresis.
Preferably, the target nucleotide sequence of Megamonas is a fragment of the 16SrRNA gene.
A kit for predicting sustained hemodialysis sarcopenia, the kit comprising reagents for detecting Megamonas abundance.
A composition comprising an agent that increases the abundance of Megamonas and its use in the manufacture of a medicament for the treatment of persistent hemodialysis sarcopenia.
The technical scheme can obtain the following beneficial effects:
the application has significantly reduced relative abundance of Megamonas (P < 0.001) in patients with persistent hemodialysis sarcopenia. The diagnostic value of the Megamonas strain on the MHD sarcopenia is expressed by ROC and AUC, the AUC is 0.787, the sensitivity is 0.867, the specificity is 0.800, and the diagnostic effect of the Megamonas strain on the MHD sarcopenia is higher.
Drawings
FIG. 1 is a schematic representation of species diversity analysis.
FIG. 2 is a difference chart of Megamonas.
FIG. 3 is a ROC curve of Megamonas for diagnosing MHD sarcopenia.
FIG. 4 is a ROC curve of Eisenbergiella bacteria diagnosing MHD sarcopenia.
Detailed Description
The application is further described with reference to the accompanying drawings:
example 1: screening for intestinal flora associated with sarcopenia:
1. study and sample collection: collecting fresh feces of feces centers of 30 MHD sarcopenia patients and 30 MHD non-sarcopenia patients, sampling, and immediately storing at-80deg.C for examination. Patient general data are shown in table 1.
TABLE 1 general patient data
Features (e.g. a character) Sarcopenia (n=30) Non-sarcopenia (n=30)
Age of 49.9±12.6 45.87±12.3
Sex (Man) 17(56.7％) 17(56.7％)
Age of dialysis 36(24.75，76.25) 35.5(16.5,65.25)
KT/V 1.53±0.31 1.43±0.29
Height (cm) 162.13±8.28 167.68±8.43
Body weight (kg) 52.35±7.74 68.30±14.97
BMI(kg/m2) 19.93±2.70 24.12±3.94
SMI(kg/m2) 6.07±0.86 8.27±1.60
Grip strength (kg) 27.15(21.25,34.20) 32.25(27.05,44.60)
Pace (m/s) 0.76±0.24 0.91±0.12
2.16S rRNA sequencing:
2.1 extraction of DNA:
genomic DNA was extracted from the samples according to the kit instructions.
2.2 determination of NDA concentration and purity:
quality of genomic DNA, including DNA concentration and purity, was checked by 1.8% agarose gel electrophoresis
2.3PCR amplification and product purification:
the V3-V4 variable region of bacterial 16S rRNA was PCR amplified using primers 338F and 806R. The PCR products were mixed in equal proportions and then subjected to column purification using a DNA purification column.
2.4Miseq library construction and sequencing:
the purified amplified fragments were constructed into libraries according to Illumina MiSeq platform standard procedure. Sequencing was performed using the Hiseq2500 platform from Illumina.
3. Data analysis:
3.1 sequence splicing and Filtering
And splicing the original sequencing sequences by using FLASH 1.2.11 software, filtering by using Trimmopic 0.33 software, and removing the chimera by using UCHIME 8.1 software to obtain a high-quality Tags sequence.
3.2OTU clustering
Sequences were OTU clustered at a level of 97% similarity using usearchh 10.0 software and single sequences and chimeras were removed during clustering. The biometric analysis was performed using an OTU at 97% level with RDP classifer, aligned using a Silva database (SSU 123), where OTU represents the operational classification unit operational taxonomic units.
3.3 differential analysis of intestinal flora species:
the Kruskal-Wallis rank sum test using SPSS 26.0 software analyzes the differential bacterial population between groups and evaluates the diagnostic value of differential bacterial genus for MHD sarcopenia using ROC curves and areas under the curves.
4. Results:
sequencing data and OTU information are shown in table 2, a representing the MHD sarcopenia group and B representing the MHD non-sarcopenia group. Species diversity analysis as shown in fig. 1, the abundance of species is reflected by the length of the curve on the horizontal axis, the wider the curve, the richer the composition of the species; uniformity of species composition is reflected by the shape of the curve, with flatter curves indicating a higher degree of uniformity of species composition.
TABLE 2 sequencing data and OTU number statistics
The results of the species differential analysis showed that the relative abundance of Megamonas was significantly reduced (P < 0.001) in patients with MHD sarcopenia compared to MHD non-sarcopenia, the differences being shown in figure 2.
Example 2: verifying the diagnostic value of Megamonas for MHD sarcopenia:
a: study and sample collection: fresh feces from the feces centers of 30 patients suffering from MHD sarcopenia and 30 patients suffering from MHD non-sarcopenia were collected as in example 1, and immediately after sampling, were placed at-80℃for storage and examination. Patient general data are shown in table 3.
TABLE 3 general patient data
Features (e.g. a character) Sarcopenia (n=30) Non-sarcopenia (n=30)
Age of 50.1±10.6 49.3±9.6
Sex (Man) 17(56.7％) 17(56.7％)
Age of dialysis 39(27.25,79.75) 36.5(17.5,66.5)
KT/V 1.74±0.35 1.65±0.33
Height (cm) 160.24±7.36 165.67±6.52
Body weight (kg) 51.34±5.37 65.39±18.85
BMI(kg/m2) 19.92±2.45 23.87±3.56
SMI(kg/m2) 5.65±0.78 7.89±1.27
Grip strength (kg) 26.54(20.45,33.20) 31.38(26.93,42.63)
Pace (m/s) 0.75±0.47 0.87±0.46
B.16S rRNA sequencing and data analysis were as in example 1.
C. Results:
the test results show that the relative abundance of Megamonas is significantly reduced in maintenance hemodialysis patients. The diagnostic value of Megamonas on MHD sarcopenia is represented by ROC and AUC, as shown in FIG. 3, the AUC is 0.787, the sensitivity is 0.867, the specificity is 0.800, and the diagnostic effect of Megamonas on MHD sarcopenia is higher.
Wherein: ROC represents subject work curve receiver operating curve; AUC represents the area under the curve area.
Example 3:
at present, anaerofoil bacteria and Eisenbergiella bacteria are also used for diagnosing or detecting sarcopenia, and when the Anaerofoil bacteria and Eisenbergiella bacteria are applied to the diagnosis of MHD sarcopenia, the inventor can obtain by experimental analysis: anaerofoil bacteria are not detected in the feces of MHD patients, probably because the relative abundance of the Anaerofoil bacteria is too low, and are not dominant bacterial groups of the feces of MHD patients, so the Anaerofoil bacteria cannot be applied to diagnosis of MHD sarcopenia.
Eisenbergiella bacteria show that in the result of detecting MHD sarcopenia, the AUC in the ROC result is only 0.626 (shown in detail in figure 4), the specificity is 0.567, the sensitivity is 0.667, the diagnostic value is low, and the maintenance hemodialysis sarcopenia cannot be well diagnosed.
The foregoing is a preferred embodiment of the present application, and modifications, obvious to those skilled in the art, of the various equivalent forms of the present application can be made without departing from the principles of the present application, are intended to be within the scope of the appended claims.

Claims (1)

1. Use of an agent for detecting the abundance of Megamonas in the intestinal flora for the preparation of a product for diagnosing sarcopenia in a patient suffering from maintenance hemodialysis, characterized in that: the relative abundance of Megamonas in patients with persistent hemodialysis sarcopenia is significantly reduced compared to patients with persistent hemodialysis non-sarcopenia.
CN202110830622.7A 2021-07-21 2021-07-21 Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient Active CN113549671B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110830622.7A CN113549671B (en) 2021-07-21 2021-07-21 Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110830622.7A CN113549671B (en) 2021-07-21 2021-07-21 Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient

Publications (2)

Publication Number Publication Date
CN113549671A CN113549671A (en) 2021-10-26
CN113549671B true CN113549671B (en) 2023-09-08

Family

ID=78132421

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110830622.7A Active CN113549671B (en) 2021-07-21 2021-07-21 Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient

Country Status (1)

Country Link
CN (1) CN113549671B (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077794A1 (en) * 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN104955466A (en) * 2012-11-23 2015-09-30 赛里斯治疗公司 Synergistic bacterial compositions and methods of production and use thereof
CN105936931A (en) * 2016-04-15 2016-09-14 山东畜牧兽医职业学院 Kit for fluorescence quantitative PCR detection of poultry-farm enterobacteriaceae drug-resistant gene and detection method thereof
CN111004740A (en) * 2019-11-29 2020-04-14 南方医科大学 Basic nutrient solution for rapidly stabilizing in-vitro intestinal flora and application thereof
CN111411150A (en) * 2020-04-22 2020-07-14 中国医学科学院北京协和医院 Intestinal flora for diagnosing sarcopenia and application thereof
CN111518927A (en) * 2019-12-05 2020-08-11 广东美格基因科技有限公司 TaqMan probe quantitative detection method for detecting pseudomonas putida and corresponding kit
CN111748640A (en) * 2020-04-22 2020-10-09 中国医学科学院北京协和医院 Application of intestinal flora in sarcopenia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955466A (en) * 2012-11-23 2015-09-30 赛里斯治疗公司 Synergistic bacterial compositions and methods of production and use thereof
WO2015077794A1 (en) * 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN105936931A (en) * 2016-04-15 2016-09-14 山东畜牧兽医职业学院 Kit for fluorescence quantitative PCR detection of poultry-farm enterobacteriaceae drug-resistant gene and detection method thereof
CN111004740A (en) * 2019-11-29 2020-04-14 南方医科大学 Basic nutrient solution for rapidly stabilizing in-vitro intestinal flora and application thereof
CN111518927A (en) * 2019-12-05 2020-08-11 广东美格基因科技有限公司 TaqMan probe quantitative detection method for detecting pseudomonas putida and corresponding kit
CN111411150A (en) * 2020-04-22 2020-07-14 中国医学科学院北京协和医院 Intestinal flora for diagnosing sarcopenia and application thereof
CN111748640A (en) * 2020-04-22 2020-10-09 中国医学科学院北京协和医院 Application of intestinal flora in sarcopenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
肝硬化患者肠道微生态与肌量减少的相关性研究;郝莎莎等;实用肝脏病杂志;第23卷(第4期);第462页右栏第1段-第465页左栏第1段，图3、4） *

Also Published As

Publication number Publication date
CN113549671A (en) 2021-10-26

Similar Documents

Publication Publication Date Title
CN111440884B (en) Intestinal flora for diagnosing sarcopenia and application thereof
CN106650312B (en) Device for detecting copy number variation of circulating tumor DNA
KR101944662B1 (en) Method for diagnosis of stroke using analysis of bacteria metagenome
CN111411150B (en) Intestinal flora for diagnosing sarcopenia and application thereof
CN106845154B (en) A device for FFPE sample copy number variation detects
CN110541026A (en) Biomarker for detecting ulcerative colitis and application
CN110819705A (en) Method for analyzing diversity and difference of intestinal flora of UC patient
Zhang et al. Development of hydrolysis probe-based real-time PCR for identification of virulent gene targets of Burkholderia pseudomallei and B. mallei—a retrospective study on archival cases of service members with melioidosis and glanders
EP3636780B1 (en) Method for diagnosing autism by analyzing bacterial metagenome
Georgiadou et al. Comparative transcriptomic analysis reveals translationally relevant processes in mouse models of malaria
CN113549671B (en) Intestinal flora for diagnosing sarcopenia of maintenance hemodialysis patient
CN113403409A (en) Bacterial species level detection and analysis method based on bacterial 16S rRNA gene sequence
CN115261499B (en) Intestinal microbial marker related to endurance and application thereof
CN110628898B (en) BAZ1B susceptibility SNP locus detection reagent and kit prepared by same
CN105733988B (en) Composition and application
CN110643700B (en) Application of KFS related gene mutation in preparation of detection kit
CN110628897B (en) KFS pathogenic gene new mutation and application thereof
CN114657270B (en) Alzheimer disease biomarker based on intestinal flora and application thereof
CN108410889B (en) ATP1A2 mutant gene for epilepsy auxiliary diagnosis and application
CN117418025A (en) Application of intestinal flora marker in diagnosis and treatment of autism
KR20240035430A (en) Methods of indirect analysis of microbiome by using swab sampling
Green et al. Modern Diagnostic Methods in the 21st Century
CN114517227A (en) Acute diarrhea marker gene and application thereof
CN116875687A (en) Screening and application of Gelson-Xinghuoka bacterial markers
CN117070627A (en) Gene composition for detecting lung adenocarcinoma tumor mutation load and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant